Syneos Health Stock Forecast, Price & News

Syneos Health's stock was trading at $57.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SYNH stock has decreased by 10.0% and is now trading at $51.58.
View which stocks have been most impacted by COVID-19.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Syneos Health.

Syneos Health is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Syneos Health.

Syneos Health Inc (NASDAQ:SYNH) posted its quarterly earnings results on Thursday, August, 6th. The company reported $0.58 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.38 by $0.20. The company earned $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Syneos Health had a return on equity of 9.63% and a net margin of 4.10%. Syneos Health's revenue was down 13.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.74 EPS.
View Syneos Health's earnings history.

Syneos Health updated its FY20 earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of $3.16-3.38 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.00. The company issued revenue guidance of $4.47-4.57 billion, compared to the consensus revenue estimate of $4.45 billion.

12 brokers have issued 12-month price objectives for Syneos Health's stock. Their forecasts range from $45.00 to $82.00. On average, they anticipate Syneos Health's share price to reach $65.33 in the next twelve months. This suggests a possible upside of 26.7% from the stock's current price.
View analysts' price targets for Syneos Health.

Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA) and Eloxx Pharmaceuticals (ELOX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Square (SQ), Icon (ICLR), Netflix (NFLX), Advanced Micro Devices (AMD), Boeing (BA), Alibaba Group (BABA), AT&T (T) and AbbVie (ABBV).

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Syneos Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.64%), ArrowMark Colorado Holdings LLC (2.34%), Bank of New York Mellon Corp (1.34%), GW&K Investment Management LLC (1.34%), FMR LLC (0.92%) and Goldman Sachs Group Inc. (0.81%). Company insiders that own Syneos Health stock include Alistair Macdonald, International Corp/Ma Advent, Jason M Meggs, John M Dineen, Jonathan Olefson, Michelle Keefe, Paul Colvin, Robert Parks and Thomas H Lee Advisors, Llc.
View institutional ownership trends for Syneos Health.

SYNH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Victory Capital Management Inc., Nuveen Asset Management LLC, Vanguard Group Inc., Charles Schwab Investment Management Inc., Bank of America Corp DE, Prudential Financial Inc., and Glenmede Trust Co. NA. Company insiders that have sold Syneos Health company stock in the last year include Alistair Macdonald, International Corp/Ma Advent, Michelle Keefe, Robert Parks, and Thomas H Lee Advisors, Llc.
View insider buying and selling activity for Syneos Health.

SYNH stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., GW&K Investment Management LLC, Avidity Partners Management LP, AQR Capital Management LLC, Premier Asset Management LLC, Principal Financial Group Inc., and Principal Financial Group Inc.. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs, John M Dineen, Jonathan Olefson, and Paul Colvin.
View insider buying and selling activity for Syneos Health.

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYNH stock can currently be purchased for approximately $51.58.

Syneos Health has a market capitalization of $5.39 billion and generates $4.68 billion in revenue each year. The company earns $131.26 million in net income (profit) each year or $2.83 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.

The official website for Syneos Health is www.syneoshealth.com.

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]